BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

Market Cap	21.27B
Revenue (ttm)	1.19B
Net Income (ttm)	138.06M
Shares Out	422.11M
EPS (ttm)	0.33
PE Ratio	153.85
Forward PE	79.34
Dividend	0.10 (0.19%)
Ex-Dividend Date	Jul 4, 2024

Volume	9,461,170
Average Volume	8,271,509
Open	52.35
Previous Close	52.78
Day's Range	51.56 - 53.55
52-Week Range	22.82 - 54.12
Beta	0.31
RSI	59.16
Earnings Date	Aug 22, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,151
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688166

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 189.17 million, a decrease of -6.57%.